Clinical study to evaluate the efficacy and safety of LH-RH agonist alternative therapy on prostate cancer patients who relapsed after combined androgen blockade.

Clinical study to evaluate the efficacy and safety of LH-RH agonist alternative therapy on prostate cancer patients who relapsed after combined androgen blockade. - Clinical study to evaluate the efficacy and safety of LH-RH agonist alternative therapy on prostate cancer patients who relapsed after combined androgen blockade.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007771

Enrollment

Registered

2012-10-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

LHRH agonistwill be changed to another LHRH agonist.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)Pathologically proven prostate cancer 2)Performance status 0-2(ECOG) 3)Age<80 years old 4)Patients who satisfy the following a)WBC>3.0x10000/uL b)hemoglobin>10.0g/dL c)platelet>10x100000/uL d)serum creatinine<2.0mg/dL e)AST<100U/L f)ALT<100U/L 5)Written informed consent can be obtained

Exclusion criteria

Exclusion criteria: 1)Patients who have not observed anti-androgen withdrawal syndrome(AWS) 2)Treated with steroid drug 3)Undergone bilateral orchidectomy 4)Treated with chemotherapy 5)Treated with anti-androgen for benign prostate hyperplasia(BPH) 6)Considered inappropriate for this study by physicians

Design outcomes

Primary

Measure	Time frame
PSA response and response duration	—

Secondary

Measure	Time frame
Time to treatment failure (TTTF) Adverse events	—

Countries

Japan

Contacts

Public ContactMikinobu Ohtani

Ibaraki Prefectural Central Hospital Department of Urology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026